Monte Rosa Therapeutics (GLUE) Common Equity: 2023-2025
Historic Common Equity for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $245.8 million.
- Monte Rosa Therapeutics' Common Equity rose 19.65% to $245.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.8 million, marking a year-over-year increase of 19.65%. This contributed to the annual value of $222.9 million for FY2024, which is 24.37% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Common Equity stood at $245.8 million for Q3 2025, which was down 8.30% from $268.1 million recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Common Equity high stood at $275.2 million for Q1 2025, and its period low was $152.5 million during Q1 2024.
- Its 3-year average for Common Equity is $219.6 million, with a median of $222.9 million in 2024.
- Its Common Equity has fluctuated over the past 5 years, first tumbled by 37.42% in 2024, then spiked by 80.41% in 2025.
- Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Common Equity stood at $179.2 million in 2023, then climbed by 24.37% to $222.9 million in 2024, then increased by 19.65% to $245.8 million in 2025.
- Its Common Equity was $245.8 million in Q3 2025, compared to $268.1 million in Q2 2025 and $275.2 million in Q1 2025.